Remission, low disease activity and improvement of pain and function in psoriatic arthritis patients treated with IL-12/23 and IL-17 inhibitors. A multicenter prospective study
The development of new biologic and targeted synthetic DMARDs can lead to good disease control. The aim of the present study was to assess the rate of remission and low disease activity, and the improvement of pain and function, in psoriatic arthritis (PsA) patients treated with new anti-IL-12/23 an...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2020-04-01
|
| Series: | Reumatismo |
| Subjects: | |
| Online Access: | https://www.reumatismo.org/index.php/reuma/article/view/1266 |
| _version_ | 1818572287719243776 |
|---|---|
| author | F.M. Perrotta A. Delle Sedie S. Scriffignano P. Volpe E. Cordisco N. Milano M. Gabini E. Lubrano |
| author_facet | F.M. Perrotta A. Delle Sedie S. Scriffignano P. Volpe E. Cordisco N. Milano M. Gabini E. Lubrano |
| author_sort | F.M. Perrotta |
| collection | DOAJ |
| description | The development of new biologic and targeted synthetic DMARDs can lead to good disease control. The aim of the present study was to assess the rate of remission and low disease activity, and the improvement of pain and function, in psoriatic arthritis (PsA) patients treated with new anti-IL-12/23 and anti-IL-17 biologic agents. A prospective 6-month study was performed. Patients fulfilling the CASPAR criteria for PsA that started ustekinumab, secukinumab and ixekizumab were enrolled and prospectively followed in a setting of clinical practice. Patients were considered in minimal disease activity (MDA), when they met at least 5/7 of the criteria previously defined. DAPSA score ≤4 was also evaluated as a remission criterion. Pain on VAS, PtGA and HAQ were also assessed in all patients. Patients achieving MDA were compared to non-MDA to identify outcome predictive factors. Of the 70 patients treated with ustekinumab, secukinumab and ixekizumab, at baseline, no patients were in MDA or had a DAPSA score ≤4. Ten patients (14.2%) were lost during the follow-up. After 6 months, MDA was achieved in 22 (31.4%) patients. DAPSA≤4 was achieved in 17 (24.2%) patients. Significant improvement in pain, PtGA and HAQ was also found. Patients naïve to anti-TNF treatment achieved more frequently MDA compared to anti-TNF-experienced patients. Male sex, high levels of CRP and absence of comorbidities were found to be predictors of MDA. In our prospective observational study, MDA was achieved in 31.4% and DAPSA remission in 24.2% of patients treated with inhibitors of IL-12/23 and IL-17, thus making this target achievable in PsA patients treated with these drugs. |
| first_indexed | 2024-12-14T18:55:09Z |
| format | Article |
| id | doaj.art-e8f2510c6da64cdc9896d162303aa8ea |
| institution | Directory Open Access Journal |
| issn | 0048-7449 2240-2683 |
| language | English |
| last_indexed | 2024-12-14T18:55:09Z |
| publishDate | 2020-04-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Reumatismo |
| spelling | doaj.art-e8f2510c6da64cdc9896d162303aa8ea2022-12-21T22:51:07ZengPAGEPress PublicationsReumatismo0048-74492240-26832020-04-0172110.4081/reumatismo.2020.1266Remission, low disease activity and improvement of pain and function in psoriatic arthritis patients treated with IL-12/23 and IL-17 inhibitors. A multicenter prospective studyF.M. Perrotta0A. Delle Sedie1S. Scriffignano2P. Volpe3E. Cordisco4N. Milano5M. Gabini6E. Lubrano7Academic Rheumatology Unit, Dipartimento di Medicina e Scienze della Salute “Vincenzo Tiberio”, Università degli Studi del Molise, CampobassoU.O. Reumatologia, Azienda Ospedaliera-Universitaria Pisana. PisaAcademic Rheumatology Unit, Dipartimento di Medicina e Scienze della Salute “Vincenzo Tiberio”, Università degli Studi del Molise, CampobassoUOC Reumatologia, Presidio Ospedaliero “Santo Spirito”. PescaraUOC di Medicina, Ambulatorio di Reumatologia, Ospedale “San Timoteo”, TermoliUOC di Medicina, Ambulatorio di Reumatologia, Ospedale “San Timoteo”, TermoliUOC Reumatologia, Presidio Ospedaliero “Santo Spirito”. PescaraAcademic Rheumatology Unit, Dipartimento di Medicina e Scienze della Salute “Vincenzo Tiberio”, Università degli Studi del Molise, CampobassoThe development of new biologic and targeted synthetic DMARDs can lead to good disease control. The aim of the present study was to assess the rate of remission and low disease activity, and the improvement of pain and function, in psoriatic arthritis (PsA) patients treated with new anti-IL-12/23 and anti-IL-17 biologic agents. A prospective 6-month study was performed. Patients fulfilling the CASPAR criteria for PsA that started ustekinumab, secukinumab and ixekizumab were enrolled and prospectively followed in a setting of clinical practice. Patients were considered in minimal disease activity (MDA), when they met at least 5/7 of the criteria previously defined. DAPSA score ≤4 was also evaluated as a remission criterion. Pain on VAS, PtGA and HAQ were also assessed in all patients. Patients achieving MDA were compared to non-MDA to identify outcome predictive factors. Of the 70 patients treated with ustekinumab, secukinumab and ixekizumab, at baseline, no patients were in MDA or had a DAPSA score ≤4. Ten patients (14.2%) were lost during the follow-up. After 6 months, MDA was achieved in 22 (31.4%) patients. DAPSA≤4 was achieved in 17 (24.2%) patients. Significant improvement in pain, PtGA and HAQ was also found. Patients naïve to anti-TNF treatment achieved more frequently MDA compared to anti-TNF-experienced patients. Male sex, high levels of CRP and absence of comorbidities were found to be predictors of MDA. In our prospective observational study, MDA was achieved in 31.4% and DAPSA remission in 24.2% of patients treated with inhibitors of IL-12/23 and IL-17, thus making this target achievable in PsA patients treated with these drugs.https://www.reumatismo.org/index.php/reuma/article/view/1266Psoriatic arthritisremissionanti-IL12/23anti-IL-17. |
| spellingShingle | F.M. Perrotta A. Delle Sedie S. Scriffignano P. Volpe E. Cordisco N. Milano M. Gabini E. Lubrano Remission, low disease activity and improvement of pain and function in psoriatic arthritis patients treated with IL-12/23 and IL-17 inhibitors. A multicenter prospective study Reumatismo Psoriatic arthritis remission anti-IL12/23 anti-IL-17. |
| title | Remission, low disease activity and improvement of pain and function in psoriatic arthritis patients treated with IL-12/23 and IL-17 inhibitors. A multicenter prospective study |
| title_full | Remission, low disease activity and improvement of pain and function in psoriatic arthritis patients treated with IL-12/23 and IL-17 inhibitors. A multicenter prospective study |
| title_fullStr | Remission, low disease activity and improvement of pain and function in psoriatic arthritis patients treated with IL-12/23 and IL-17 inhibitors. A multicenter prospective study |
| title_full_unstemmed | Remission, low disease activity and improvement of pain and function in psoriatic arthritis patients treated with IL-12/23 and IL-17 inhibitors. A multicenter prospective study |
| title_short | Remission, low disease activity and improvement of pain and function in psoriatic arthritis patients treated with IL-12/23 and IL-17 inhibitors. A multicenter prospective study |
| title_sort | remission low disease activity and improvement of pain and function in psoriatic arthritis patients treated with il 12 23 and il 17 inhibitors a multicenter prospective study |
| topic | Psoriatic arthritis remission anti-IL12/23 anti-IL-17. |
| url | https://www.reumatismo.org/index.php/reuma/article/view/1266 |
| work_keys_str_mv | AT fmperrotta remissionlowdiseaseactivityandimprovementofpainandfunctioninpsoriaticarthritispatientstreatedwithil1223andil17inhibitorsamulticenterprospectivestudy AT adellesedie remissionlowdiseaseactivityandimprovementofpainandfunctioninpsoriaticarthritispatientstreatedwithil1223andil17inhibitorsamulticenterprospectivestudy AT sscriffignano remissionlowdiseaseactivityandimprovementofpainandfunctioninpsoriaticarthritispatientstreatedwithil1223andil17inhibitorsamulticenterprospectivestudy AT pvolpe remissionlowdiseaseactivityandimprovementofpainandfunctioninpsoriaticarthritispatientstreatedwithil1223andil17inhibitorsamulticenterprospectivestudy AT ecordisco remissionlowdiseaseactivityandimprovementofpainandfunctioninpsoriaticarthritispatientstreatedwithil1223andil17inhibitorsamulticenterprospectivestudy AT nmilano remissionlowdiseaseactivityandimprovementofpainandfunctioninpsoriaticarthritispatientstreatedwithil1223andil17inhibitorsamulticenterprospectivestudy AT mgabini remissionlowdiseaseactivityandimprovementofpainandfunctioninpsoriaticarthritispatientstreatedwithil1223andil17inhibitorsamulticenterprospectivestudy AT elubrano remissionlowdiseaseactivityandimprovementofpainandfunctioninpsoriaticarthritispatientstreatedwithil1223andil17inhibitorsamulticenterprospectivestudy |